Jonathan A Webster
Overview
Explore the profile of Jonathan A Webster including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
193
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Palmisiano N, Lee J, Claxton D, Paietta E, Alkhateeb H, Park J, et al.
EJHaem
. 2024 Oct;
5(5):951-956.
PMID: 39415930
Introduction: Relapsed or refractory (r/r) acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL) remains a therapeutic challenge. Preclinical data in both B- and T-ALL suggests synergy of venetoclax (VEN) with...
2.
Jia J, Ji W, Saliba A, Csizmar C, Ye K, Hu L, et al.
Cell Death Differ
. 2024 Mar;
31(4):405-416.
PMID: 38538744
BH3 mimetics, including the BCL2/BCLX/BCLw inhibitor navitoclax and MCL1 inhibitors S64315 and tapotoclax, have undergone clinical testing for a variety of neoplasms. Because of toxicities, including thrombocytopenia after BCLX inhibition...
3.
Pasca S, Haldar S, Ambinder A, Webster J, Jain T, Dalton W, et al.
Haematologica
. 2023 Sep;
109(3):948-952.
PMID: 37731390
No abstract available.
4.
5.
Kagan A, Garrison D, Anders N, Webster J, Baker S, Yegnasubramanian S, et al.
Clin Transl Sci
. 2023 Jun;
16(8):1309-1322.
PMID: 37345219
Although DNA methyltransferase inhibitors (DNMTis), such as azacitidine and decitabine, are used extensively in the treatment of myelodysplastic syndromes and acute myeloid leukemia, there remain unanswered questions about DNMTi's mechanism...
6.
Sanber K, Ye K, Tsai H, Newman M, Webster J, Gojo I, et al.
Leuk Lymphoma
. 2023 Feb;
64(4):846-855.
PMID: 36744656
The combination of venetoclax and hypomethylating agent (HMA/venetoclax) has emerged as a treatment option for patients with de novo acute myeloid leukemia (AML) who are unfit to receive intensive chemotherapy....
7.
Webster J, Reed M, Tsai H, Ambinder A, Jain T, DeZern A, et al.
Transplant Cell Ther
. 2023 Jan;
29(3):182.e1-182.e8.
PMID: 36587740
Patients age ≥55 years with acute lymphoblastic leukemia (ALL) fare poorly with conventional chemotherapy, with a 5-year overall survival (OS) of ∼20%. Tyrosine kinase inhibitors and novel B cell-targeted therapies...
8.
Webster J, Luznik L, Gojo I
Front Oncol
. 2022 Jan;
11:812207.
PMID: 34976845
With advances in allogeneic hematopoietic stem cell transplant (allo-HCT), disease relapse has replaced transplant-related mortality as the primary cause of treatment failure for patients with acute myeloid leukemia (AML). The...
9.
Zeidner J, Vincent B, Ivanova A, Moore D, McKinnon K, Wilkinson A, et al.
Blood Cancer Discov
. 2021 Nov;
2(6):616-629.
PMID: 34778801
Significance: Immune-checkpoint blockade with pembrolizumab was tolerable and feasible after high-dose cytarabine in R/R AML, with encouraging clinical activity, particularly in refractory AML and those receiving treatment as first salvage...
10.
Webster J, Robinson T, Blackford A, Warlick E, Ferguson A, Borrello I, et al.
Leuk Res
. 2021 Nov;
111:106737.
PMID: 34768161
Purpose: Chronic myeloid leukemia (CP-CML) patients can achieve undetectable minimal residual disease (UMRD) and discontinue tyrosine kinase inhibitors (TKIs). Cellular immunity plays an important role in CML disease control. We...